Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response

被引:27
作者
Brackman, Deanna J. [1 ]
Giacomini, Kathleen M. [1 ,2 ]
机构
[1] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA
关键词
CANCER RESISTANCE PROTEIN; CELL LUNG-CANCER; BREAST-CANCER; MULTIDRUG-RESISTANCE; ROSUVASTATIN PHARMACOKINETICS; GENETIC POLYMORPHISMS; ALZHEIMERS-DISEASE; TRANSPORTER ABCG2; RISK-FACTORS; PHASE-II;
D O I
10.1002/cpt.903
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Reverse translational research takes a bedside-to-bench approach, using sophisticated basic research to explain the biological mechanisms behind observed clinical data. For transporters, which play a role in human disease and drug response, this approach offers a distinct advantage over the typical translational research, which often falters due to inadequate in vitro and preclinical animal models. Research on ABCG2, which encodes the Breast Cancer Resistance Protein, has benefited immensely from a reverse translational approach due to its broad implications for disease susceptibility and both therapeutic and adverse drug response. In this review, we describe the success of reverse translational research for ABCG2 and opportunities for further studies.
引用
收藏
页码:233 / 242
页数:10
相关论文
共 50 条
  • [31] Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells
    Xie, Yi
    Nakanishi, Takeo
    Natarajan, Karthika
    Safren, Lowell
    Hamburger, Anne W.
    Hussain, Arif
    Ross, Douglas D.
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2015, 1849 (03): : 317 - 327
  • [32] Development of precision medicine approaches based on inter-individual variability of BCRP/ABCG2
    Chen, Liming
    Manautou, Jose E.
    Rasmussen, Theodore P.
    Zhong, Xiao-bo
    ACTA PHARMACEUTICA SINICA B, 2019, 9 (04) : 659 - 674
  • [33] Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic
    Shiozawa, K
    Oka, M
    Soda, H
    Yoshikawa, M
    Ikegami, Y
    Tsurutani, J
    Nakatomi, K
    Nakamura, Y
    Doi, S
    Kitazaki, T
    Mizuta, Y
    Murase, K
    Yoshida, H
    Ross, DD
    Kohno, S
    INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (01) : 146 - 151
  • [34] A fluorescence-based in vitro assay for drug interactions with breast cancer resistance protein (BCRP, ABCG2)
    Mahringer, Anne
    Delzer, Juergen
    Fricker, Gert
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2009, 72 (03) : 605 - 613
  • [35] Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study
    Mahmoud A. A. Ibrahim
    Esraa A. A. Badr
    Alaa H. M. Abdelrahman
    Nahlah Makki Almansour
    Ahmed M. Shawky
    Gamal A. H. Mekhemer
    Faris Alrumaihi
    Mahmoud F. Moustafa
    Mohamed A. M. Atia
    Cell Biochemistry and Biophysics, 2021, 79 : 189 - 200
  • [36] In Vitro and In Vivo Evaluation of ABCG2 (BCRP) Inhibitors Derived from Ko143
    Zechner, Melanie
    Jaramillo, Claudia A. Castro
    Zubler, Nadine S.
    Taddio, Marco F.
    Mu, Linjing
    Altmann, Karl-Heinz
    Kramer, Stefanie D.
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (10) : 6782 - 6797
  • [37] Effects of α-Adrenoceptor Antagonists on ABCG2/BCRP-Mediated Resistance and Transport
    Takara, Kohji
    Yamamoto, Kazuhiro
    Matsubara, Mika
    Minegaki, Tetsuya
    Takahashi, Minoru
    Yokoyama, Teruyoshi
    Okumura, Katsuhiko
    PLOS ONE, 2012, 7 (02):
  • [38] Induction of ABCG2/BCRP restricts the distribution of zidovudine to the fetal brain in rats
    Fernanda Filia, Maria
    Marchini, Timoteo
    Mauricio Minoia, Juan
    Ignacio Roma, Martin
    Teresa De Fino, Fernanda
    Carlos Rubio, Modesto
    Copello, Guillermo J.
    Evelson, Pablo A.
    Noemi Peroni, Roxana
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2017, 330 : 74 - 83
  • [39] The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids
    Holland, M. L.
    Lau, D. T. T.
    Allen, J. D.
    Arnold, J. C.
    BRITISH JOURNAL OF PHARMACOLOGY, 2007, 152 (05) : 815 - 824
  • [40] The Anthelmintic Triclabendazole and Its Metabolites Inhibit the Membrane Transporter ABCG2/BCRP
    Barrera, Borja
    Otero, Jon A.
    Egido, Estefania
    Prieto, Julio G.
    Seelig, Anna
    Alvarez, Ana I.
    Merino, Gracia
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (07) : 3535 - 3543